News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
64,630 Results
Type
Article (1875)
Company Profile (6)
Press Release (62749)
Section
Business (29481)
Career Advice (60)
Deals (4434)
Drug Delivery (5)
Drug Development (7093)
Employer Resources (11)
FDA (1282)
Job Trends (1821)
News (40561)
Policy (2266)
Tag
2027 Genetown Standard (1)
Academia (140)
Accelerated approval (6)
Allergies (14)
Alliances (2363)
ALS (22)
Alzheimer's disease (108)
Antibody-drug conjugate (ADC) (30)
Approvals (1369)
Artificial intelligence (25)
Autoimmune disease (11)
Automation (2)
Bankruptcy (5)
Best Places to Work (1711)
Biosimilars (10)
Biotechnology (7)
Bladder cancer (40)
Brain cancer (4)
Breast cancer (100)
Cancer (554)
Cardiovascular disease (62)
Career advice (54)
CAR-T (13)
CDC (1)
Cell therapy (53)
Cervical cancer (3)
Clinical research (6718)
Collaboration (83)
Compensation (116)
Complete response letters (4)
COVID-19 (216)
CRISPR (5)
C-suite (43)
Cystic fibrosis (14)
Data (835)
Depression (12)
Diabetes (51)
Diagnostics (672)
Digital health (4)
Diversity (2)
Diversity, equity & inclusion (3)
Drug discovery (14)
Drug pricing (5)
Duchenne muscular dystrophy (53)
Earnings (27294)
Editorial (3)
Employer branding (1)
Employer resources (8)
Events (6412)
Executive appointments (38)
FDA (1785)
Fibrodysplasia Ossificans Progressiva (2)
Frontotemporal dementia (8)
Funding (76)
Gene editing (12)
Generative AI (1)
Gene therapy (43)
GLP-1 (131)
Government (298)
Guidances (252)
Healthcare (2024)
HIV (3)
Huntington's disease (4)
IgA nephropathy (17)
Immunology and inflammation (21)
Immuno-oncology (4)
Indications (13)
Infectious disease (236)
Inflammatory bowel disease (19)
Influenza (8)
Intellectual property (9)
Interviews (4)
IPO (3302)
IRA (3)
Job creations (178)
Job search strategy (52)
JPM (3)
Kidney cancer (1)
Labor market (5)
Layoffs (31)
Leadership (1)
Legal (404)
Liver cancer (8)
Lung cancer (83)
Lymphoma (65)
Management (2)
Manufacturing (41)
MASH (26)
Medical device (1626)
Medtech (1632)
Mergers & acquisitions (1243)
Metabolic disorders (167)
Multiple sclerosis (24)
NASH (2)
Neurodegenerative disease (22)
Neuropsychiatric disorders (11)
Neuroscience (240)
NextGen: Class of 2026 (542)
Non-profit (247)
Now hiring (4)
Obesity (88)
Opinion (11)
Ovarian cancer (14)
Pain (12)
Pancreatic cancer (30)
Parkinson's disease (27)
Partnered (5)
Patents (16)
Patient recruitment (23)
Peanut (7)
People (2114)
Pharmacy benefit managers (2)
Phase 1 (1569)
Phase 2 (2699)
Phase 3 (2893)
Pipeline (1411)
Policy (10)
Postmarket research (280)
Preclinical (456)
Press Release (3)
Prostate cancer (24)
Radiopharmaceuticals (17)
Rare diseases (73)
Real estate (282)
Recruiting (4)
Regulatory (1949)
Reports (10)
Research institute (133)
Resumes & cover letters (6)
RSV (7)
Schizophrenia (14)
Series A (10)
Series B (11)
Sickle cell disease (8)
Special edition (1)
Spinal muscular atrophy (11)
Sponsored (1)
Startups (129)
Stomach cancer (2)
Supply chain (2)
Tariffs (7)
The Weekly (3)
Vaccines (63)
Venture capital (6)
Weight loss (71)
Women's health (9)
Date
Last 7 days (53)
Last 30 days (169)
Last 365 days (4127)
2026 (211)
2025 (4234)
2024 (4564)
2023 (5059)
2022 (5824)
2021 (6103)
2020 (5494)
2019 (4608)
2018 (3355)
2017 (2977)
2016 (2247)
2015 (2936)
2014 (2020)
2013 (1226)
2012 (1485)
2011 (1752)
2010 (1659)
Location
Africa (48)
Alabama (10)
Alaska (1)
Arizona (21)
Arkansas (1)
Asia (3489)
Australia (459)
California (1370)
Canada (413)
China (136)
Colorado (108)
Connecticut (57)
Delaware (88)
Europe (10022)
Florida (176)
Georgia (88)
Idaho (5)
Illinois (87)
India (1)
Indiana (73)
Japan (57)
Kansas (30)
Kentucky (5)
Louisiana (8)
Maine (14)
Maryland (152)
Massachusetts (951)
Michigan (109)
Minnesota (66)
Missouri (20)
Montana (2)
Nevada (21)
New Hampshire (10)
New Jersey (496)
New York (331)
North Carolina (151)
Northern California (699)
Ohio (61)
Oregon (1)
Pennsylvania (316)
Puerto Rico (1)
South America (67)
South Carolina (1)
Southern California (570)
Tennessee (10)
Texas (178)
United States (5097)
Utah (49)
Virginia (13)
Washington D.C. (4)
Washington State (139)
Wisconsin (9)
64,630 Results for "72".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Novo Nordisk files for FDA approval of a higher dose of Wegovy® injection 7.2 mg
November 27, 2025
·
6 min read
Press Releases
Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72
January 6, 2026
·
8 min read
Press Releases
Quadriga BioSciences Announces Encouraging Interim Phase II Results of LAT1-targeted QBS72S in Breast Cancer Patients with Leptomeningeal Disease
December 4, 2025
·
4 min read
Press Releases
Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers
December 15, 2025
·
7 min read
Press Releases
Gene Prediction Tools Market Drives at 18.72% CAGR by 2034, reports Healthcare Experts
September 11, 2025
·
1 min read
Press Releases
Abpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell Engager
November 5, 2025
·
9 min read
Press Releases
Hemato Oncology Testing Market Size to Hit USD 15.72 Billion by 2034
August 5, 2025
·
1 min read
Press Releases
Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions
August 26, 2025
·
3 min read
Press Releases
Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer
October 19, 2025
·
32 min read
Press Releases
Subcutaneous RYBREVANT®▼(amivantamab) delivers promising 45 percent overall response rate with median duration of response of 7.2 months in recurrent or metastatic head and neck cancer
October 19, 2025
·
14 min read
1 of 6,463
Next
